Varenicline

Varenicline is a partial agonist selective for a4β2 nicotinic acetylcholine receptor. Varenicline, as the tartrate salt, is a powder which is a white to off-white to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1).


Adult Dose
Dose: 0.5 mg
Single Dose: 0.5 (0.5)
Frequency: 24 hourly
Route: PO
Instructions: Day 1-3, Once daily. The patient should set a date to stop smoking. Varenicline dosing should start one week before this date. It should be taken after eating and with a full glass of water. Smoking cessation therapies are more likely to succeed for patients who are motivated to stop smoking and who are provided additional advice and support. Patients should be provided with appropriate educational materials and counseling to support the quit attempt.
Neonatal
Paedriatic
Characteristics
. The Molecular Weight of Varenicline is 361.35.
Contraindications
Varenicline
Effects
The symptomatic adverse reactions produced by Varenicline are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Insomnia, Abnormal dreams.
Indications
Varenicline is primarily indicated in conditions like Smoking cessation.
Interactions
No data regarding the interactions of Varenicline was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Tabs Store Between 20°C-25°C.
Warnings
Patients who can not tolerate adverse effects of Varenicline may have the dose lowered temporarily or permanently. Patients should be treated with Varenicline for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks treatment with Varenicline is recommended to further increase the likelihood of long-term abstinence. Patients who do not succeed in stopping smoking during 12 weeks of initial therapy, or who relapse after treatment, should be encouraged to make another attempt once factors contributing to the failed attempt have been identified and addressed.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.